These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 31192282)
21. Polidocanol foam sclerotherapy in the treatment of hemorrhoidal disease in patients with bleeding disorders: a multicenter, prospective, cohort study. Salgueiro P; Rei A; Garrido M; Rosa B; Oliveira AM; Pereira-Guedes T; Morais S; Castro-Poças F Tech Coloproctol; 2022 Aug; 26(8):615-625. PubMed ID: 35217937 [TBL] [Abstract][Full Text] [Related]
22. Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review. Bossart S; Daneluzzi C; Cazzaniga S; Ramelet AA; Uthoff H; Seyed Jafari SM; Baumgartner M; Hunger RE; Heidemeyer K; Willenberg T J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):274-283. PubMed ID: 36196455 [TBL] [Abstract][Full Text] [Related]
23. Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report. Itou C; Koizumi J; Hashimoto T; Myojin K; Kagawa T; Mine T; Imai Y Cardiovasc Intervent Radiol; 2014 Jun; 37(3):800-4. PubMed ID: 24170168 [TBL] [Abstract][Full Text] [Related]
24. Interim results of bleomycin-polidocanol foam sclerotherapy as a highly efficient technique for venous malformations. Yang X; Chen H; Gu H; Jin Y; Hu L; Hua C; Wang Y; Sun Y; Yu W; Lin X J Vasc Surg Venous Lymphat Disord; 2020 Nov; 8(6):1066-1073. PubMed ID: 32284311 [TBL] [Abstract][Full Text] [Related]
25. Successful Sclerotherapy for Cervicofacial Macrocystic Lymphatic Malformations Using Polidocanol and Pingyangmycin Combined Foam Sclerosants. Wang Q; Zhou Q; Zhao Z; Liu C; Zheng J Lymphat Res Biol; 2022 Oct; 20(5):507-513. PubMed ID: 35041550 [No Abstract] [Full Text] [Related]
26. Ultrasound-guided polidocanol foam sclerotherapy for symptomatic giant hepatic cyst: A single-center experience. Eso Y; Shimizu H; Takai A; Takahashi K; Seno H Hepatol Res; 2022 Jun; 52(6):557-565. PubMed ID: 35355375 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Rabe E; Otto J; Schliephake D; Pannier F Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the Safety and Efficacy of Foam Sclerotherapy With 1: 2 Polidocanol to Air Ratio Versus 1: 4 Ratio for the Treatment of Reticular Veins of the Lower Extremities. Hoss E; Kollipara R; Boen M; Alhaddad M; Goldman MP Dermatol Surg; 2020 Dec; 46(12):1715-1720. PubMed ID: 32947299 [TBL] [Abstract][Full Text] [Related]
29. Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique. Rao J; Goldman MP Dermatol Surg; 2005 Jan; 31(1):19-22. PubMed ID: 15720090 [TBL] [Abstract][Full Text] [Related]
30. Properties of polidocanol foam in view of its use in sclerotherapy. Nastasa V; Samaras K; Ampatzidis Ch; Karapantsios TD; Trelles MA; Moreno-Moraga J; Smarandache A; Pascu ML Int J Pharm; 2015 Jan; 478(2):588-96. PubMed ID: 25433198 [TBL] [Abstract][Full Text] [Related]
31. Treatment of male varicoceles by transcatheter polidocanol foam sclerotherapy: evaluation of clinical success, complications, and patients' satisfaction with regard to alternative techniques. Ali A; Wirth S; Treitl KM; Treitl M Eur Radiol; 2015 Oct; 25(10):2889-97. PubMed ID: 25796582 [TBL] [Abstract][Full Text] [Related]
32. Sclerotherapy with 3% polidocanol foam in the treatment of hemorrhoidal disease: unveiling the missing pieces for a comprehensive evaluation. Gallo G; Dezi A; Grossi U; Picciariello A Front Surg; 2023; 10():1344724. PubMed ID: 38179315 [No Abstract] [Full Text] [Related]
33. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Ceulen RP; Bullens-Goessens YI; Pi-VAN DE Venne SJ; Nelemans PJ; Veraart JC; Sommer A Dermatol Surg; 2007 Mar; 33(3):276-81. PubMed ID: 17338683 [TBL] [Abstract][Full Text] [Related]
34. Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins. Star P; Connor DE; Parsi K Phlebology; 2018 Apr; 33(3):150-162. PubMed ID: 28166694 [TBL] [Abstract][Full Text] [Related]
35. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Yamaki T; Nozaki M; Iwasaka S Dermatol Surg; 2004 May; 30(5):718-22; discussion 722. PubMed ID: 15099313 [TBL] [Abstract][Full Text] [Related]
36. Sclerotherapy for III- and IV-degree hemorrhoids: Results of a prospective study. Lisi G; Gentileschi P; Spoletini D; Passaro U; Orlandi S; Campanelli M Front Surg; 2022; 9():978574. PubMed ID: 36117836 [TBL] [Abstract][Full Text] [Related]
38. The effect of the calibre and length of needle on the stability of sclerosing foam. Skuła M; Hobot J; Czaja J; Simka M Phlebology; 2021 May; 36(4):322-328. PubMed ID: 33236673 [TBL] [Abstract][Full Text] [Related]
39. Comparison of polidocanol foam versus bleomycin polidocanol foam for treatment of venous malformations. He B; Yang B; Nie QQ; Zhang JB; Chen J; Liu P; Fan XQ; Ye ZD J Vasc Surg Venous Lymphat Disord; 2023 Jan; 11(1):143-148. PubMed ID: 35940448 [TBL] [Abstract][Full Text] [Related]
40. Sclerotherapy for congenital vascular malformations with mixing foam of polidocanol and liquid of bleomycin. Yang WH; Xiang XJ; Li HL Phlebology; 2023 Aug; 38(7):451-457. PubMed ID: 37318342 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]